IE 11 is a very old Browser and it`s not supported on this site
Financial Report Financial statements

Balance sheet as at December 31 

in CHF

 

Notes

 

2021

 

2020

Current assets

 

 

 

 

 

 

Cash and cash equivalents

 

 

 

146 964

 

25 022

Other current receivables

 

 

 

6 080 156

 

5 639 574

 

 

 

 

6 227 120

 

5 664 596

Non-current assets

 

 

 

 

 

 

Investments

 

 

 

1 177 069 500

 

1 177 069 500

 

 

 

 

1 177 069 500

 

1 177 069 500

Total assets

 

 

 

1 183 296 620

 

1 182 734 096

 

 

 

 

 

 

 

Current liabilities

 

 

 

 

 

 

Other current liabilities

 

2.1

 

403 102

 

381 190

Accrued expenses

 

 

 

610 326

 

440 145

 

 

 

 

1 013 428

 

821 335

Total liabilities

 

 

 

1 013 428

 

821 335

 

 

 

 

 

 

 

Shareholders' equity

 

 

 

 

 

 

Share capital

 

2.2

 

11 080 000

 

11 080 000

Legal capital reserves

 

 

 

 

 

 

– Paid-in capital reserve 1)

 

 

 

20 579 224

 

20 579 224

Legal profit reserves

 

 

 

 

 

 

– General legal reserve

 

 

 

4 500 000

 

4 500 000

– Reserve for treasury shares 2)

 

 

 

9 205 288

 

8 241 195

Other reserves

 

 

 

217 622 468

 

218 586 561

Retained earnings

 

5/6

 

919 296 212

 

918 925 781

 

 

 

 

1 182 283 192

 

1 181 912 761

Total liabilities and shareholders' equity

 

 

 

1 183 296 620

 

1 182 734 096

1 Of which CHF 20 441 000 not confirmed by the Swiss Tax Authorities due to present regulation

2 For treasury shares held by subsidiaries

The financial statements were approved by the Board of Directors of BB Biotech AG on February 15, 2022.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer